biostudies-literatureUnknown7(2)Hsu YR<h4>Introduction</h4>Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a target of antibody-drug conjugate therapy for NSCLC. High expression of CEACAM5 has been reported in approximately 25% of patients with lung adenocarcinoma. However, CEACAM5 expression has not been systematically examined in a real-world and large patient population with NSCLC. There are also limited data on the prognostic impact of CEACAM5 protein expression.<h4>Methods</h4>We assessed CEACAM5 protein expression by immunohistochemistry in two separate cohorts of patients with NSCLC to include both routine clinical biopsy and resection specimens, using the anti-CEACAM5 clone 769 antibody assay protocol and scoring scheme for the tusamitamab ravtansine clinical trials. Expression levels were categoJTO clinical and research reports100943https://www.ebi.ac.uk/biostudies/studies/S-EPMC12828397biostudies-literatureThe Landscape of CEACAM5 Expression by Immunohistochemistry in NSCLC.PMC12828397Hou LAzaizeh ABates MHsu YRAlmutrafi ALi QTsao MSPham NAHueniken KfalseThe Landscape of CEACAM5 Expression by Immunohistochemistry in NSCLC.<h4>Introduction</h4>Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is a target of antibody-drug conjugate therapy for NSCLC. High expression of CEACAM5 has been reported in approximately 25% of patients with lung adenocarcinoma. However, CEACAM5 expression has not been systematically examined in a real-world and large patient population with NSCLC. There are also limited data on the prognostic impact of CEACAM5 protein expression.<h4>Methods</h4>We assessed CEACAM5 protein expression by immunohistochemistry in two separate cohorts of patients with NSCLC to include both routine clinical biopsy and resection specimens, using the anti-CEACAM5 clone 769 antibody assay protocol and scoring scheme for the tusamitamab ravtansine clinical trials. Expression levels were catego2026-01-01T00:00:00Z2026 Feb2026-06-16T04:47:12.023Z2026-06-16T03:06:45.383ZS-EPMC128283974158472110.1016/j.jtocrr.2025.100943